Opdyta 40mg tablet | Apple pharmaceuticals

OPDYTA 40MG

It is a prescription drug which is used under the supervision of a doctor
Opdyta 40mg belongs to a human monoclonal antibody which stops the interaction between PD-1 and its ligands, PD-L1 and PD-L2.

Opdyta 40mg is an IgG4 kappa immunoglobulin which has a calculated molecular mass of 146 kDa. It is expressed in a recombinant Chinese Hamster Ovary (CHO) cell line.

Opdyta 40mg is also known as an immune checkpoint inhibitor. Sometimes these drugs are called targeted therapies because they target specific proteins (receptors) on the surface of cells.

INDICATION

Opdyta 40mg is indicated for the treatment of patients having :
Melanoma
Non-Small Cell Lung Cancer
Kidney (Renal Cell) Cancer

MECHANISM

Binding of these ligands to the PD-1 receptor occur on T cells, prohibits T cell multiplication and cytokine production. Upregulation of the PD-1 ligands occurs in some tumor and signaling via this pathway can provide to the prohibition of active T-cell immune surveillance of tumor. Nivolumab belongs to human immunoglobulin G4 (IgG4) monoclonal antibody which binds to the PD-1 receptor and stops its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated prevention of the immune response, containing the anti-tumor immune response, resulting in reduced tumor growth.

DOSAGE

Opdyta recommended dosage for unresectable or metastatic melanoma: 
As a single agent is either 240mg every 2 weeks or 480mg every 4 weeks given as IV infusion over 30 minutes until disease progression or unacceptable toxicity

With ipilimumab: 
The recommended dose of Opdyta is 1mg/kg administrated as an intravenous infusion over 30 minutes, followed by ipilimumab 3mg/kg given as IV over 90 minutes on the same day. Duration 3 weeks of max 4 doses, after completing combination dose continue the single agent treatment.

COMMON SIDE EFFECTS

Fatigue
Lymphocytopenia (Low White Blood Cells)
Low Sodium
Shortness of breath
Musculoskeletal Pain
Decreased Appetite
Cough

DRUG INTERACTION

No formal pharmacokinetic drug interaction studies

PRECAUTION

Immune-mediated pneumonitis may appear to the patients, hence withhold for moderate and permanently discontinue for serious or life-threatening pneumonitis.
Other clinically important and possible fatal immune-mediated side effects (eg, myocarditis, rhabdomyolysis, myositis, uveitis, iritis, pancreatitis) can appear after therapy discontinuation. Severe infusion reactions resulted (rare, <1%); discontinue if severe or life-threatening; break or slow rate of infusion in patients with mild or moderate infusion reactions

STORAGE

Store at under refrigeration at 2℃ to 8℃.

MISSED DOSE

If you missed a dose take it as soon as possible, if time reach for next dose, then skip missed dose and continue regular schedule. Avoid taking two doses at a time. Avoid taking missed dose within 12hrs of the next dose.


FOR MORE INFORMATION

EMAIL:


applepharmaceutical@gmail.com

PHONE:


91- 9987711567

Comments

Popular posts from this blog

Cabozantinib (Cometriq, Cabometyx) tablet Online | Apple pharmaceuticals

Evertor 10mg tablet - Everolimus | Myapplepharma

Everotas 5mg tablet - Everolimus | Myapplepharma